Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
Jenny Seligmann, MBChB, PhD
Fortunato Ciardiello, MD, PhD
Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Elizabeth R. Plimack, MD, MS, FASCO
Shilpa Gupta, MD
Collaborative Insights to Solve the Puzzle of Bladder Cancer
Daniel P. Petrylak, MD
Evan Y. Yu, MD
Understanding the Expanding Role of Antibody-Drug Conjugates in Bladder Cancer
Lillibeth Velasco, MSN, RN
Reviewing the Latest Bladder Cancer Practice Guidelines
Patient Perspectives on Bladder Cancer
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
Expert Viewpoint: Optimizing Breast Cancer Treatment
William J. Gradishar, MD
Erica L. Mayer, MD, MPH
Peter Schmid, FRCP, MD, PhD
Emerging Treatment Approaches for EBC
Management of HR+, HER2- High-Risk EBC
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Aparna R. Parikh, MD
Innovations in Oncology Learning Center From Guidelines to Practice: Gastrointestinal Cancers
Sara Lonardi, MD
Alan Venook, MD
Management of HER2-Low MBC Following First-Line Disease Progression
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.